These insights are relevant for rational development of metabolic anti-glioma therapies, because our data predict that inhibitors of glycolysis, such as HK2/3 and PKM2 [61, 62] may be the most promising for IDH1WT glioma, whereas inhibitors of the TCA cycle and the glutamatolysis pathway such as metformin, chloroquine and epigallocatechin-3-gallate [3, 56] may possess a therapeutic index in IDH1MUT glioma. The gene discussed is HK2; the disease is central nervous system cancer.